Financial Results for the First Three Months of Fiscal Year Ending December 2017

Ι	Summary	Information	P.1
	1	Financial Results	P.1
	2	Financial Conditions	P.1
Π	Financial F	Results for the First Three Months of FY2017	P.2
	1	Statement of Income	P.2
	2	Sales of Products	P.4
	3	Balance Sheet	P.5
	4	Capital Expenditures	P.6
	5	Depreciation/Amortization	P.6
	6	Research and Development	P.6
Ш	Financial F	Forecasts for the FY2017	P.7
	1	Statement of Income	P.7
	2	Sales of Products	P.9
	3	Capital Expenditures	P.10
	4	Depreciation/Amortization	P.10
	5	Dividends	P.10
[In	nportant no	tes on forward-looking statements】	P.10

☆ This material is prepared based on Japan GAAP.

times Amounts are rounded down to the nearest million yen.

April 27, 2017




I Summary Information

① Financial Results


The forecasts for the FY2017 have not been changed from the previous forecasts announced at the FY2016 financial results announcement on February 2, 2017.

(Millions of Yen)	Fi	FY2016 est three months A	FY2017 First three months B	Change <i>B-A</i>	Change (%) (<i>B-A)/A</i>	FY2016 Full year	FY2017 Full year forecast C	Progress ratio (%) <i>B/C</i>
Net sales		13,740	13,608	(131)	(1.0)	60,206	64,500	21.1
Operating income		1,184	533	(651)	(54.9)	3,819	5,300	10.1
Ordinary income		1,223	555	(668)	(54.6)	3,999	5,400	10.3
Net income		803	388	(414)	(51.6)	2,839	3,900	10.0
(Reference)								
R&D expenses		1,042	1,152	110	10.6	4,654	4,820	23.9
Earnings per share (EPS)	(¥)	28.39	13.85	(14.54)		100.41	139.04	
Return on equity (ROE)	(%)	1.0	0.5	(0.5)		3.4	_	
Ratio of ordinary income to total assets	(%)	1.2	0.6	(0.6)		4.1	_	
Ratio of operating income to net sales	(%)	8.6	3.9	(4.7)		6.3	_	
Return on assets (ROA)	(%)	0.8	0.4	(0.4)		2.9	_	









Full year

First three months

② Financial Conditions

(Millions of Yen)		December 31, 2016 <i>A</i>	March 31, 2017 <i>B</i>	Change <i>B-A</i>	Change (%) <i>(B-A)/A</i>
Total assets		98,525	97,849	(676)	(0.7)
Total equity		83,556	83,244	(312)	(0.4)
Equity ratio	(%)	84.8	85.1	0.3	
Book value per share (BPS)	(¥)	2,978.80	2,967.63	(11.17)	

I Financial Results for the First Three Months of FY2017

① Statement of Income


(Millions of Yen)	FY2016	FY2017	Change	Change
	First three months			(%)
	<u>A</u>	<u>B</u>	B-A	(B-A)/A
Net sales	13,740	13,608	(131)	(1.0)
Sales of products	13,609		(227)	(1.7)
Renal disease and hemodialysis	5,829	5,116	(713)	(12.2)
Skin disease	2,299	2,145	(153)	(6.7)
Allergens	302	431	128	42.6
HIV infection	3,761	4,371	610	16.2
Other	1,417	1,317	(99)	(7.0)
Other sales	130	225	95	73.5
Cost of sales	6,475	6,802	326	5.0
Cost of products sold	6,459	6,788	328	5.1
Other cost	15	13	(1)	(12.3)
Gross profit	7,264	6,806	(458)	(6.3)
Selling, general and	6,079	6,272	192	3.2
administrative expenses	0,079	0,272	192	5.2
R&D expenses	1,042	1,152	110	10.6
Others	5,037	5,120	82	1.6
Operating income	1,184	533	(651)	(54.9)
Non-operating income	38	22	(15)	_
Non-operating expenses	0	1	1	_
Ordinary income	1,223	555	(668)	(54.6)
Extraordinary loss	14	16	1	_
Income before income taxes	1,209	539	(670)	(55.4)
Income taxes	405	150	(255)	
Net income	803	388	(414)	(51.6)

(Reference) Ratio to net sales


(%)	FY2016	FY2017	Change
(70)	First three months	First three months	
	A	В	B-A
Cost of sales	47.1	50.0	2.9
SG&A	44.3	46.1	1.8
R&D expenses	7.6	8.5	0.9
Operating income	8.6	3.9	(4.7)
Ordinary income	8.9	4.1	(4.8)
Net income	5.8	2.9	(2.9)

[Factors in increase/decrease compared with the same term of the last fiscal year]

Net Sales (¥13,608 million : Decrease ¥131 million year-on-year)



Operating income (¥533 million : Decrease ¥651 million year-on-year)



Major facto	Major factors in increase/decrease			
Cost of sale	es : Increase with increase in sales quantity			
R&D expen	ses : Increase in co-development expenses			

Ordinary income (¥555 million : Decrease ¥668 million year-on-year)

Special remarks: None

Net income (¥388 million : Decrease ¥414 million year-on-year)

Special remarks: None

② Sales of Products

illions of Yen)	FY2016	FY2017	Change	Change
F	A <i>A</i>	First three months	B-A	(%) (B-A)/A
ales of Products	13,609	13,382	(227)	(1.7
REMITCH Oral anti-pruritus agent [Renal disease and hemodialysis]	3,255	2,753	(502)	(15.4
Truvada Antiviral agent for HIV [HIV infection]	2,890	1,797	(1,092)	(37.8
ANTEBATE %1 Topical corticosteroid [Skin disease]	1,514	1,426	(88)	(5.3
Genvoya X2 Antiviral agent for HIV [HIV infection]	-	1,285	1,285	
Riona Agent for hyperphosphatemia [Renal disease and hemodialysis]	1,205	1,219	13	1
Descovy X3 Antiviral agent for HIV [HIV infection]	-	1,199	1,199	
BIO-THREE Viable bacterial preparations [Other]	554	563	8	1
KAYEXALATE ×1 Agent for hyperkalemia [Renal disease and hemodialysis]	507	475	(31)	(6.
FUTHAN X1 Protease inhibitor [Renal disease and hemodialysis]	560	424	(136)	(24.
LOCOID ×1 Topical corticosteroid [Skin disease]	338	336	(2)	(0.
CEDARTOLEN %1 Japanese cedar pollinosis (Allergen Immunoth [Allergens]	188 herapy)	271	82	43
URINORM X1 Uricosuric agent [Renal disease and hemodialysis]	300	242	(57)	(19.
Magsent Tocolysis in threatened premature labor Eclampsia-suppressing and treatment [Other]	237	223	(14)	(6.
ZEFNART Topical antifungal agent [Skin disease]	209	209	(0)	(0.
Stribild Antiviral agent for HIV [HIV infection]	814	48	(766)	(94.
Others	1,032	906	(126)	(12.

(References) Sales and ratio of in-house products

(Millions of Yen)	FY2016	FY2017	Change	Change
	First three months	First three months First three months		(%)
	А	В	B-A	(B-A)/A
Sales of in-house products	3,825	3,631	(194)	(5.1)
Ratio of in-house	6) 28.1	27.1	(1,0)	
product sales	0) 20.1	27.1	(1.0)	—

③ Balance Sheet

(Millions of Yen)	December 31, 2016	March 31, 2017	Change	Change (%)	Component ratio (%)
	A	В	B-A	(B-A)/A	(March 31, 2017)
Current assets	80,123	79,310	(812)	(1.0)	81.1
Cash and deposits	22,393	20,266	(2,127)		
Deposits in the cash	7,091	6,477	(614)		
management system	,,051	0,11,1	(011)		
Notes and accounts	26,560	25,060	(1,500)		
receivable-trade	_0,000	_0,000	(1)000)		
Short-term	11,102	13,706	2,603		
investment securities					
Inventories	10,606	11,205	598		
Others	2,368	2,595	227		
Noncurrent assets	18,401	18,538	136	0.7	18.9
Property, plant and equipment	5,752	5,577	(175)		
Intangible assets	896	884	(12)		
Investments and other assets	11,752	12,076	324		
Investment securities	3,877	4,236	359		
Long-term prepaid expenses	6,486	6,432	(53)		
Others	1,389	1,407	18		
Total assets	98,525	97,849	(676)	(0.7)	100.0
Current liabilities	13,310	13,000	(310)	(2.3)	13.3
Accounts payable-trade	6,698	7,169	471		
Accounts payable-other	3,178	3,055	(122)		
Income taxes payable	767	221	(545)		
Accrued employees' bonuses	676	1,310	634		
Others	1,990	1,242	(748)		
Long-term liabilities	1,658	1,604	(53)	(3.2)	1.6
Total liabilities	14,969	14,605	(364)	(2.4)	14.9
Shareholders' equity	82,993	82,708	(284)	(0.3)	84.5
Unrealized gain on	558	529	(28)	(5.1)	0.6
available-for-sale securities			. ,		
Subscription rights to shares	4	5	1	25.7	0.0
Total equity	83,556	83,244	(312)	(0.4)	85.1
Total liabilities and equity	98,525	97,849	(676)	(0.7)	100.0

Major factors in increase/decreas	<u>e</u>
(Current assets)	
Notes and accounts	: Decrease with decrease in sales
receivable-trade	Decrease with decrease in sales
Short-term	: Increase with acquisition of money trust
investment securities	. Therease with acquisition of money trast
Inventories	: Increase in new products

④ Capital Expenditures

(Millions of Yen)	FY2016 First three months <i>A</i>	FY2017 First three months B	Change _{B-A}	Change (%) (B-A)/A
Capital expenditures	136	128	(8)	(6.2)
PP&E	73	56	(17)	(23.8)
Intangible assets	62	72	9	14.4

Descriptions of capital expenditures

PP&E : Investment mainly in manufacturing facilities aiming to maintain and improve productivity Intangible assets : Investment in software aiming to streamline operations

5 Depreciation/Amortization

(Millions of Yen)	FY2016 First three months A	FY2017 First three months	Change _{B-A}	Change (%) _{(B-A)/A}
Depreciation and amortization of intangible assets	347	299	(48)	(13.9)
Amortization of long-term prepaid expenses	251	262	11	4.4

6 Research and Development

Development		Formulation/		Developn	nent stage (d	omestic)			
code	Indication	Route of administration	Phase I	Phase II	Phase III	Phase II Application		Remarks	
Renal disease and hen	nodialysis								
JTT-751 [Riona® Tablets]	Iron-deficiency anemia	Oral		Phase II				 Licensing agreement signed with Keryx for development and commercialization of hyperphosphatemia drug in Japan Co-development with JT Riona filed by JT has been approved as a treatment of hyperphosphatemia on January 17,2014, and is being promoted and distributed by Torii. 	
Allergens									
TO-203 [MITICURE® House Dust Mite Sublingual . Tablets]	House dust mite induced allergic asthma (Allergen Immunotherapy)	Sublingual tablet		Phase (Study cor	eⅡ/Ⅲ npleted※)			Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan -In-house *Examining the future development policy	
	House dust mite induced allergic rhinitis in children (Allergen Immunotherapy)	Sublingual tablet				Application		Licensing agreement signed with ALK for providing exclusive development and sales rights in Japan In-house NDA filing by Torii on March 24, 2017	
ТО-206	Japanese cedar pollinosis (Allergen Immunotherapy)	Sublingual tablet				Application		•In-house •NDA filing by Torii on December 25, 2015	

Updates since the previous announcement on February 2, 2017

•TO-203(MITICURE® House Dust Mite Sublingual Tablets) NDA filing for the indication of allergic rhinitis in children by Torii on March 24, 2017.

More information is available at the following website: http://www.torii.co.jp/en/release/2016/20160810 E.pdf http://www.torii.co.jp/en/release/2016/20161028 E.pdf

Ⅲ Financial Forecasts for the FY2017

The forecasts for the FY2017 have not been changed from the previous forecasts announced at the FY2016 financial results announcement on February 2, 2017.


① Statement of Income

(Millions of Yen)	FY2016	FY2017 forecast	Change	Change (%)
	А	В	B-A	(B-A)/A
Net sales	60,206	64,500	4,293	7.1
Sales of products	59,620	62,900	3,279	5.5
Renal disease and hemodialysis	25,141	26,400	1,258	5.0
Skin disease	9,811	9,490	(321)	(3.3)
Allergens	1,485	2,450	964	64.9
HIV infection	17,225	18,660	1,434	8.3
Other	5,956	5,900	(56)	(0.9)
Other sales	586	1,600	1,013	173.0
Cost of sales	30,287	31,700	1,412	4.7
Gross profit	29,919	32,800	2,880	9.6
SG&A	26,099	27,500	1,400	5.4
R&D expenses	4,654	4,820	165	3.6
Others	21,445	22,680	1,234	5.8
Operating income	3,819	5,300	1,480	38.8
Ordinary income	3,999	5,400	1,400	35.0
Net income	2,839	3,900	1,060	37.3

(Reference) Ratio to net sales


(%)	FY2016	FY2017 forecast	Change
	A	В	B-A
Cost of sales	50.3	49.1	(1.2)
SG&A	43.4	42.7	(0.8)
R&D expenses	7.7	7.5	(0.2)
Operating income	6.3	8.2	1.9
Ordinary income	6.6	8.4	1.8
Net income	4.7	6.0	1.3

[Factors in increase/decrease compared with the FY2016]



Net sales (¥64,500 million : Increase ¥4,293 million year-on-year)

Operating income (¥5,300 million : Increase ¥1,480 million year-on-year)



Major factors in incr	ease/decrease
Cost of sales	: Increase in net sales
Others	: Increase in sales promotion expenses

Ordinary income (¥5,400 million : Increase ¥1,400 million year-on-year)

Special remarks: None

Net income (¥3,900 million : Increase ¥1,060 million year-on-year)

Special remarks: None

Sales of Products

A	В	B-A	(%) (B-A)/A
59,620	62,900	3,279	5.5
13,645	13,600	(45)	(0.3)
5,634	7,550	1,915	34.0
-	6,750	6,750	-
6,277	6,030	(247)	(3.9)
12,754	5,740	(7,014)	(55.0)
1,865	5,590	3,724	199.6
2,455	2,550	94	3.9
2,178	2,150	(28)	(1.3)
2,462	2,100	(362)	(14.7)
1,352	1,360	7	0.5
1,275	1,360	84	6.6
937	1,260	322	34.4
)			
1,165	1,200	34	2.9
1,219	1,000	(219)	(18.0
2,371	400	(1,971)	(83.1
4,023	4,260	236	5.9
	- 6,277 12,754 1,865 2,455 2,178 2,462 1,352 1,275 937 937 1,165 1,219 2,371	- 6,750 6,277 6,030 12,754 5,740 1,865 5,590 2,455 2,550 2,178 2,150 2,462 2,100 1,352 1,360 1,275 1,360 937 1,260 1,219 1,000 2,371 400	- 6,750 6,750 6,277 6,030 (247) 12,754 5,740 (7,014) 1,865 5,590 3,724 2,455 2,550 94 2,455 2,550 94 2,462 2,100 (362) 1,352 1,360 7 1,275 1,360 84) 937 1,260 322 1,165 1,200 34 1,219 1,000 (219) 2,371 400 (1,971)

%1 In-house products

X2 Launched on July 8, 2016

X3 Launched on January 27, 2017

(References) Sales and ratio of in-house products

(Millions of Yen)		FY2016	FY2017 forecast	Change	Change (%)
		A	В	B-A	(B-A)/A
Sales of in-house produc	cts	16,316	16,440	123	0.8
Ratio of in-house product sales	(%)	27.4	26.1	(1.3)	_

③ Capital Expenditures

(Millions of Yen)	FY2016	FY2017 forecast	Change	Change (%)
	A	В	B-A	(B-A)/A
Capital expenditures	891	1,192	300	33.7
PP&E	644	964	319	49.5
Intangible assets	246	228	(18)	(7.7)

 Descriptions of capital expenditures

 PP&E
 : Investment mainly in manufacturing facilities aiming to maintain and improve productivity

 Intangible assets
 : Investment in software aiming to streamline operations

④ Depreciation/Amortization

(Millions of Yen)	FY2016 <i>A</i>	FY2017 forecast <i>B</i>	Change <i>B-A</i>	Change (%) <i>(B-A)/A</i>
Depreciation and amortization of intangible assets	1,339	1,240	(99)	(7.4)
Amortization of long-term prepaid expenses	1,018	1,056	37	3.6

⑤ Dividends

		FY2016	FY2017 forecast	Change	Change (%)
		A	В	B-A	(B-A)/A
Dividends per share	(¥)	48	48	0	0.0
Dividends payout ratio	(%)	47.8	34.5	(13.3)	_

[Important notes on forward-looking statements]

The forecasts presented in this material are forward-looking statements. Reflecting assumptions based on information available on the date of publication, these statements are subject to inherent risks and uncertainties. Accordingly, unforeseen factors may cause actual results to differ materially from the projections contained herein.

Torii will not necessarily revise this material regardless of any new information, future events or other results. At the present moment, the following matters may be pointed out as risks or uncertain factors that could affect the Company's future results (but such risks or uncertain factors are not limited to these):

- \diamondsuit Changes in Pharmaceutical and Medical Device Law, Other Acts or Regulations
- \diamondsuit Delay or Discontinuance of Research and Development
- \diamondsuit Drug Price Listing and Revisions
- \Diamond Adverse Drug Reactions
- \diamond Stoppage of Product Supply and Product Recall
- \Diamond Litigation Risk